Abstract: A candle holder comprises a housing for securing a candle; the housing including first thermochromic material formed on the housing and second thermochromic material formed on the thermochromic material. The first thermochromic material changes a perceivable state of the first thermochromic material when an ambient temperature of first thermochromic material is above a first pre-determined activation temperature, the perceivable state of the first thermochromic material being visually perceivable or non-visually perceivable. The second thermochromic material changes a perceivable state of the second thermochromic material when an ambient temperature of second thermochromic material is above a second pre-determined activation temperature, the perceivable state of the second thermochromic material being visually perceivable or non-visually perceivable. The perceivable state of the first thermochromic material is different from the perceivable state of the second thermochromic material.

Abstract: Provided herein are solid textile treating compositions; compositions containing colorants stabilized with one or more colorant stabilizers; compositions containing colorants that do not need to be stabilized by one or more colorant stabilizers; solid wash cycle conditioning agents; liquid textile treating compositions; cleaning agent compositions containing these; methods of making these; methods of treating textiles with these; textiles treated by these; containers containing the compositions; and methods of visually designating when a composition has reached or passed its pull date.

Abstract: The present invention relates to treatment compositions containing polymer systems that provide stability and benefit agent deposition as well as methods of making and using same. Such treatment compositions may be used for example as through the wash and/or through the rinse fabric enhancers as well as unit dose treatment compositions.

Abstract: The present invention relates to fabric softener compositions as well as the methods of making and using same. Such liquid fabric softener compositions comprise a quaternary ammonium ester fabric softening active, cellulose fibers and a hydrotrope. Such fabric softener compositions exhibit improved viscosity stability after addition of a hydrotrope while also delivering the softening benefits that are desired by consumers.

Abstract: The present invention comprises chlorinated and non-chlorinated alkaline cleaning compositions for removal of proteinaceous and fatty soils at low temperature, i.e. less than 120° F., with little or no deleterious affect on cleaning performance. According to the invention, applicants have found that adding additional alkalinity makes protein removal more difficult and reducing the amount of alkalinity actually improves performance. According to the invention optimized combinations of chlorine and alkalinity components for low temperature cleaning as well as a surfactant system optimized for low temperature fatty soil removal are disclosed.

Abstract: The present invention relates to liquid laundry detergent compositions comprising a polyetheramine.

Abstract: The present invention relates to a biodegradable detergent composition, which can contain viable cells or enzymes and acts as a replacement for the chemical detergents. The biodegradable detergent composition, comprising of: bio surfactant; polyols; biopolymer; organic acid; small chain peptide; essential oil; and stabilizers. The biodegradable detergent composition has a pH value of less than about 3.60, Titratable Acidity % between about 9.0-12.0, HLB value between about 14 to about 16.5, E24 value between about 73 and about 79. The biodegradable detergent composition has MALDI-TOF MS spectra in the m/z range from about 513.1 to about 2847.7 with peak mass value range from about 1375.8 m/z to about 2009.2 m/z. Further, the present invention relates to a method of manufacturing the biodegradable detergent composition.

Abstract: The present invention provides a domestic laundry cleaning composition, said composition comprising an anionic surfactant, an alkyl ether carboxylic acid dispersant; and a lipid esterase.

Abstract: A laundry care composition including: (a) at least one laundry care ingredient and (b) a leuco composition. The laundry care composition after 30 days of storage at 25° C. provides a whiteness benefit to cotton upon washing that is greater than the initial whiteness benefit. Methods of treating textiles with such laundry care compositions.

Abstract: The present invention is directed towards mixtures comprising (A) 90 to 99.999% by weight of racemic methyl glycine diacetic acid (MGDA) or of MGDA with predominantly the L-isomer in an enantiomeric excess of up to 9.5% or their respective mono-, di- or trialkali metal or mono-, di- or triammonium salts, and (B) in total 0.001 to 10% by weight of the diacetic acid derivative of aspartate as free acid or as mono-, di-, tri- or tetraalkali metal salt or as mono-, di-, tri- or tetraammonium salt, percentages referring to the sum from (A) and (B).

Abstract: A consumer product composition comprises a consumer product adjunct ingredient, a microcapsule, and deposition polymer disposed on an outer surface of the microcapsule. The deposition polymer has a Water Uptake Value (WUV) of at least about 2 grams per gram, as determined according to the WATER UPTAKE VALUE TEST METHOD. The microcapsule comprises a shell material encapsulating a core material, wherein the shell material comprises a polyacrylate and the core material comprises a benefit agent.

Abstract: A dryer-activated product having a plurality of discrete dryer sheets having a non-woven fibrous substrate, each dryer sheet having at least a first portion, a second portion, and a frangible boundary between the first portion and the second portion, and each of the first portion and the second portion having at least about 0.35 grams of a fabric conditioning active composition.

Abstract: The present invention relates to a process for preparing a spray-dried laundry detergent particle, wherein the process includes the step of contacting zeolite to monomeric organic carboxylic acid in an aqueous mixture, wherein the aqueous mixture has a pH of 4.2 or less, wherein the aqueous mixture includes detersive surfactant, wherein the aqueous mixture is substantially free of silicate salt, and wherein the aqueous mixture is substantially free of carbonate salt, wherein the zeolite reacts with the monomeric organic carboxylic acid to form silica, wherein the aqueous mixture is spray-dried to form a spray-dried laundry detergent particle, wherein the particle includes: detersive surfactant; monomeric organic carboxylic acid; and silica, wherein the particle is substantially free of silicate salt, and wherein the particle is substantially free of carbonate salt.

Abstract: A device and method for recovering energy from a hot medium, in particular from hot wort or hot mash for a beer brewery, including a first heat exchanger device for a heat transfer medium that is arranged in particular downstream of a device for heating, boiling or keeping wort or mash warm and is designed such that the heat transfer medium can be heated while cooling preferably wort or mash, wherein at least one heat consumer of the brewery is heated with the heat transfer medium. The heat transfer medium cooled down during heating the heat consumer can be recirculated to the first heat exchanger device in the circuit.

Abstract: The invention provides an automated apparatus of cell culture having tanks of culture medium, of growth factors and of cells to be cultured, an incubator having a thermostated enclosure which houses a cell culture vessel, and control computer system. A supporting and agitation device of the culture vessel is provided in the enclosure, and the culture vessel is formed by a bag having at least one inlet port connected to the tanks and one outlet port connected devices for harvesting and storage of the cells after culture, these harvesting and storage devices and tanks being located outside the enclosure and being connected to the cell expansion bag ports by conduits which together with the cell expansion bag form a preassembled module passing through a wall of the enclosure.

Abstract: A bioprocess management system includes a bioprocess management controller for electronically interfacing with at least one bioreactor and at least one analyzer. Each bioreactor is configured to maintain cells based on a set of bioreactor operating parameters and to output bioreactor data. Each analyzer is configured to analyze at least one sample taken from at least one bioreactor and to output analyzer data for each sample. The bioprocess controller is configured to receive bioreactor data and analyzer data in real-time. Furthermore, the bioprocess controller is configured to correlate, in real-time, analyzer data from at least one analyzer with bioreactor data from at least one corresponding bioreactor. Additionally, the bioprocess controller is configured to output real-time data relating to at least one bioreactor operating parameter. The real-time data is based at least in part on correlated data from at least one analyzer and at least one corresponding bioreactor.

Abstract: A culture system comprises: a preparatory culture vessel and a main culture vessel that accommodate cells and a solution; a main stage that holds the preparatory culture vessel and the main culture vessel; a connecting tube that connects the culture vessels; a valve that opens and closes the connecting tube; and a rotating mechanism that rotates the main stage and imparts a height difference between the culture vessels to transfer the cells and solution by dropping between the culture vessels.

Abstract: The present disclosure relates to a method for preparing an aglycone or hydrolyzed glycoside converted from a glycoside and, specifically, to a method for preparing an aglycone or hydrolyzed glycoside from a glycoside by converting a glycoside into an aglycone form or hydrolyzed glycoside by using a microorganism producing ?-glycosidase, and then recovering the aglycone or hydrolyzed glycoside accumulated in the cells of the microorganism.

Abstract: Provided herein is a method for obtaining flowable oil comprising the steps of providing a population of oil-producing microorganisms; recovering oil from the microorganisms, wherein the oil is at a first temperature; reducing the first temperature over a first period of time to a second temperature; and applying mechanical energy to the oil during the first period of time thereby producing the flowable oil.

Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.

Abstract: This invention relates to an agent for inducing a callus comprising a compound represented by Formula (I) or a hydrolysis product of an amide bond thereof: wherein Ar1 represents phenyl substituted with substituent or substituents selected from alkoxy and methylenedioxy; Ar2 represents phenyl substituted with halogen; R1 and R2 each represent hydrogen, alkyl, cyano, or carboxyl; R1 and R2 may together form oxo; R3 to R10 each represent hydrogen or methyl; and R3 and R4, R5 and R6, R7 and R8, and/or R9 and R10 may together form oxo; a method for inducing a callus and a method for plant transformation using such agent for inducing a callus.

Abstract: A process for producing a 3D tissue culture model by (a) printing a drop of bio-ink to a substrate; (b) printing a drop of activator to the drop of bio-ink to form a hydrogel droplet; (c) repeating steps (a) and (b) in any order to form a hydrogel mold adapted to receive a drop containing cells; (d) printing a drop containing cells to the hydrogel mold; and (e) repeating steps (a) and (b) in any order to form a 3D tissue culture model comprising the cells encapsulated in the hydrogel mold.

Abstract: A borophosphate glass composition including B2O3, P2O5, and CaO, and optionally a source additive selected from: Li2O, Na2O, K2O, Al2O3, ZnO, MgO, Fe2O3/FeO, CuO/Cu2O, and mixtures thereof, as defined herein. Also disclosed are bioactive compositions or substrates including the disclosed borophosphate glass composition, and at least one live cell. Also disclosed are methods of inhibiting or increasing the relative amount of species containing boron, phosphorous, or both, being released into an aqueous solution from aborophosphate glass composition defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein. Also disclosed are related glass compositions that exclude one of B2O3, P2O5, and CaO.

Abstract: This disclosure provides an improved system for culturing human embryonic stem cells. The cells are cultured in suspension so as to maximize the production capacity of the culture environment. The new culture system of this invention allows for bulk proliferation of hES cells in a more cost-effective manner, which facilitates commercial production of important products for use in human therapy.

Abstract: Human pluripotent stem cells are differentiated in vitro into forebrain subdomain structures, which are then fused to generate an integrated system for use in analysis, screening programs, and the like.

Abstract: Described is the efficient and robust generation of oligodendrocyte progenitor cells (OPCs) and oligodendrocytes from pluripotent stem cells (PSCs). The protocols provided recapitulate the major steps of oligodendrocyte differentiation, from neural stem cells to OLIG2+ progenitors, and then to O4+ OPCs, in a significantly shorter time than the 120-150 days required by previous protocols. Furthermore, O4+ OPCs are able to differentiate into MBP+ mature oligodendrocytes in vitro, and to myelinate axons in vivo when injected into immuno-compromised Shiverer mice, providing proof of concept that transplantation of PSC-derived cells for remyelination is technically feasible.

Abstract: Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes IL-13 or a variant thereof that binds interleukin-13R?2 (IL13R?2), a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.

Abstract: Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same.

Abstract: Devices for non-invasive, label-free separation of particles in liquid, including circulating tumors cells in blood, are provided. Embodiments of the disclosure provide for devices employing magnetic fluids and magnets for separation of circulating tumor cells from blood. Methods for separation of particles including circulating tumor cells are also provided.

Abstract: The present invention provides methods and compositions for inducing pluripotency in differentiated mammalian cells. In particular, the methods include mechanically aggregating the cells into discrete masses or embryoid-like bodies and treated them with a small molecule compound. Provided herein are the compositions of the compounds which are derived from programin (e.g., reversine).

Abstract: The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.

Abstract: A method of forming a tier of an array of memory cells within an array area, the memory cells individually comprising a capacitor and an elevationally-extending transistor, the method comprising using two, and only two, sacrificial masking steps within the array area of the tier in forming the memory cells. Other methods are disclosed, as are structures independent of method of fabrication.

Abstract: Bacteria with tumor-targeting capability express, surface displayed, secreted and/or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.

Abstract: The present disclosure provides compositions, methods, kits, systems and apparatus that are useful for nucleic acid polymerization. In particular, modified polymerases and biologically active fragments thereof are provided that allow for nucleic acid amplification. In some aspects, the disclosure provides modified polymerases having lower systematic error as compared to a reference polymerase. In one aspect, the disclosure relates to modified polymerases useful for nucleic acid sequencing, genotyping, copy number variation analysis, paired-end sequencing and other forms of genetic analysis. In some aspects, the disclosure relates to modified polymerases useful for the generation of nucleic acid libraries or nucleic acid templates. In some aspects, the disclosure relates to the identification of homologous amino acid mutations that can be transferred across classes or families of polymerases to provide novel polymerases with altered properties.

Abstract: Isolated polypeptides with lipase activity; polynucleotides encoding the polypeptides; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the polypeptides for cleaning are disclosed.

Abstract: Disclosed herein are CRISPR/Cas9-based gene activation systems that include a fusion protein of a Cas9 protein and a protein having histone acetyltransferase activity, and methods of using said systems.

Abstract: The present invention relates to polypeptides having trehalase activity. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using a trehalase of the invention, in particular a process of producing a fermentation product, such as ethanol.

Abstract: The present invention generally relates to the field of fermentation technology and microorganisms useful for such fermentations. The invention also relates to materials including nucleic acids and proteins useful for altering fermentation characteristics of microorganisms, and to microorganisms comprising such nucleic acids and/or proteins. In particular, the invention relates to materials for conferring, modifying or reducing microbial stress resistance.

Abstract: Provided are compositions, e.g., multiplexed platforms or systems, to screen for molecules, e.g., small molecule active agents such as drugs, that inhibit enzymes such as proteases. Provided are cell-based or multiplexed platforms for monitoring or assay the activity of a protease. Provided are cell-based assays and multiplexed systems for the monitoring of enzyme, activity such as proteolytic cleavage on the cell surface, where optionally the protein, e.g., an enzyme, can be naturally expressed on the cell surface or engineered to be expressed on the cell's surface. Provided are cells and stable cell lines expressing an “assay construct” and an enzyme of interest, where optionally one cell or cell line expresses both the “assay construct” and the enzyme, or two different cells or independent cell lines are used and mixed in the assay, where one expresses the “assay construct” with the enzyme substrate and the second expressing the enzyme.

Abstract: The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide wherein the heavy chain comprises at least one mutation selected from the group consisting of: —the mutation which consists of the substitution of the glutamic acid residue (E) at position 255 of Seq. ID No. 1 by a glutamine residue (Q), an asparagine residue (N), a serine residue (S), an alanine residue (A), or a tyrosine residue (Y); —the mutation which consists of the substitution of the glutamic acid residue (E) at position 256 of Seq. ID No. 1 by a glutamine residue (Q); and —the mutation which consists of the substitution of the glutamic acid residue (E) at position 258 of Seq. ID No. 1 by a glutamine residue (Q).

Abstract: Factor IX/IXa variants and methods of use thereof are disclosed.

Abstract: The present invention relates to a method for producing a lysine carboxylase mutant strain, characteristics of the mutant strain, a gene encoding the lysine decarboxylase mutant strain, and a method for producing cadaverine using the same. The present invention provides lysine decarboxylase derived from E. coli improved through a protein engineering variation. In addition, the lysine decarboxylase mutant strain of the present invention increases activity, pH stability, and thermal stability at the time of producing cadaverine, thereby reducing production costs, through increasing a yield and productivity.

Abstract: The present invention provides methods for the non-covalent surface display of proteins of interest (POI), in particular for Fc-domain containing proteins such as antibodies. The inventive method may be used to screen and select proteins of interest of a desired phenotype. The present invention further discloses polynucleotides and proteins and methods of producing the same, which may be used in carrying out the inventive method.

Abstract: Provided are methods, compositions, reagents, kits that are useful for detecting a specific nucleic acid region in genome with high efficiency and high sensitivity.

Abstract: Disclosed herein are methods of using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) 9-based epigenomic editing systems for high-throughput screening of regulatory element function.

Abstract: Methods and compositions are provided herein for preparing high-throughput cDNA sequencing libraries.

Abstract: RNA editing is achieved using oligonucleotide constructs comprising (i) a targeting portion specific for a target nucleic acid sequence to be edited and (ii) a recruiting portion capable of binding and recruiting a nucleic acid editing entity naturally present in the cell. The nucleic acid editing entity, such as ADAR, is redirected to a preselected target site by means of the targeting portion, thereby promoting editing of preselected nucleotide residues in a region of the target RNA which corresponds to the targeting portion.

Abstract: The present disclosure provides double stranded nucleic acid comprising first and second oligonucleotides wherein the second oligonucleotide is complementary to the first oligonucleotide. At least one of the first and second oligonucleotides comprises a 5? modified nucleoside or 5? modified nucleotide having Formula IIb: wherein Bx is a heterocyclic base moiety, T2 is an internucleoside linking group linked to one of the oligonucleotides, and each of q1 to q7 are selected from a list of substituents. In certain embodiments, T2 is a phosphodiester or phosphorothioate linkage and formula IIb is a 5?-nucleotide. In certain embodiments, T2 is a non-phosphate linkage and formula IIb is a 5?-nucleoside. In certain embodiments, the present double stranded nucleic acid provides oligonucleotides that are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

Abstract: The present invention relates to oligonucleotide inhibitors of the TSC22D4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in a mammal.

Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.